ProCE Banner Series

Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice

Register now for this CME/CE/CPE-certified interactive workshop series on the latest advances in incorporating CD38 antibodies into treatment regimens to improve outcomes in patients with multiple myeloma and discussion on how to provide more equitable access to high-quality multiple myeloma care.

To Register: Please click the green Learn More button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  ACPE
  | AMA
  | ANCC
Credits Available

1.0

Who Should Attend

This educational program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma.

All Events

Past Events

November

14

2023

Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice

6:30 PM - 7:30 PM Eastern Time (ET)

In-person

Private Event, Pembrooke Pines, Florida

November

14

2023

Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice

7:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event, Franklin Square, New York

November

15

2023

Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice

8:00 AM - 9:00 AM Eastern Time (ET)

Virtual

Private Event | Host Group in NY, Plattsburgh, New York

December

07

2023

Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice

6:30 PM - 7:30 PM Eastern Time (ET)

In-person

Private Event | Host Group in NY, Oakland Gardens, New York

December

12

2023

Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice [Open Registration]

7:30 AM - 8:30 AM Pacific Time (PT)

Virtual

Private Event | Host Group in ID, Post Falls, Idaho

January

08

2024

Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice

11:30 AM - 12:30 PM Eastern Time (ET)

In-person

Private Event | Host Group in MD, Baltimore, Maryland

January

09

2024

Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice

6:30 PM - 7:30 PM Central Time (CT)

In-person

Private Event | Host Group in TX, Houston, Texas

January

11

2024

Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice [Open Registration]

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group DC, Washington, District of Columbia

January

29

2024

Recent Progress With CD38 Antibodies to Improve Outcomes in Multiple Myeloma: Expert Guidance for Clinical Practice [Open Registration]

7:00 PM - 8:00 PM Pacific Time (PT)

Virtual

CCO Simulcast | Host Group CA, Oakland, California

Topics

  • Rationale for Targeting CD38 in Multiple Myeloma
  • Overall Survival With CD38 Antibodies in Transplant-Eligible Patients With Myeloma
  • Optimizing Clinical Outcomes With CD38 Antibodies for Non‒Transplant-Eligible Patients With Myeloma
  • Barriers to Health Equity in Myeloma

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize the use of anti-CD38 monoclonal antibodies in the treatment of patients with multiple myeloma.

Target Audience
This educational program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate CD38-targeted antibodies into treatment of patients with transplant-eligible multiple myeloma to improve MRD and OS
  • Apply results of recent clinical trial to treatment selection and sequencing for patients with relapsed/refractory multiple myeloma
  • Appropriately mitigate and manage adverse events associated with CD38 antibody therapy in patients with multiple myeloma
  • Improve awareness of racial and socioeconomic barriers to equitable access to high-quality myeloma care, including clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-227-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Sanofi.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191